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Objectives: The protozoan parasite Giardia lamblia causes the intestinal disease giardiasis, which may lead to
acute and chronic diarrhoea in humans and various animal species. For treatment of this disease, several drugs
such as the benzimidazole albendazole, the nitroimidazole metronidazole and the nitrothiazolide nitazoxanide
are currently in use. Previously, a G. lamblia nitroreductase 1 (GlNR1) was identified as a nitazoxanide-binding
protein. The aim of the present project was to elucidate the role of this enzyme in the mode of action of the
nitro drugs nitazoxanide and metronidazole.
Methods: Recombinant GlNR1 was overexpressed in both G. lamblia and Escherichia coli (strain BL21). The sus-
ceptibility of the transfected bacterial and giardial cell lines to nitazoxanide and metronidazole was analysed.
Results: G. lamblia trophozoites overexpressing GlNR1 had a higher susceptibility to both nitro drugs. E. coli were
fully resistant to nitazoxanide under both aerobic and semi-aerobic growth conditions. When grown semi-
aerobically, bacteria overexpressing GlNR1 became susceptible to nitazoxanide.
Conclusions: These findings suggest that GlNR1 activates nitro drugs via reduction yielding a cytotoxic product.
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Introduction
Giardia lamblia (syn. Giardia duodenalis; Giardia intestinalis), a fla-
gellated protozoan, is the most common causative agent of per-
sistent diarrhoea worldwide.1 For antigiardial chemotherapy only
a few effective drugs are available, namely the nitroheterocyclic
drugs tinidazole, metronidazole, furazolidone, the substituted
acridine quinacrine, the aminoglycoside paromomycin and the
benzimidazole albendazole.2–4 In 2000, the nitrothiazolide nita-
zoxanide was introduced as an alternative option.5,6
Concerning the mode of action of metronidazole and related
drugs with nitro groups, the current evidence suggests that the
nitro group is reduced to a toxic nitro radical via a redox mech-
anism involving the pyruvate:ferredoxin oxidoreductase (PFOR)
system3,7 or other enzymes such as nitroreductases.8 However,
it is not clear how nitazoxanide exerts its antiparasitic activity.
Nitazoxanide inhibits recombinant bacterial PFORs by a mechan-
ism involving the abstraction of a proton from the thiamine pyr-
ophosphate vitamin co-factor of PFOR through the nitazoxanide
anion, thereby inhibiting the production of acetyl-coenzyme A
and CO2 necessary for energy metabolism.
9,10 According to this
model, nitazoxanide would display its antimicrobial activity
without the involvement of nitro reduction.10
We have previously identified a nitroreductase from G. lamblia
(GlNR1) as a nitazoxanide-binding protein. The activity of recom-
binant GlNR1 on dinitrotoluene was inhibited in vitro by nitazox-
anide. However, reduction of nitazoxanide or metronidazole in
vitro could not be detected.11 In another study, we found that
a nitazoxanide-resistant clone of G. lamblia WBC6 exhibited sig-
nificantly lower GlNR1 mRNA levels compared with the wild-type
WBC6.12
These findings suggested the following three hypotheses for
the involvement of GlNR1 in the mode of action of nitazoxanide:
(i) GlNR1 activates nitazoxanide by partial reduction, yielding a
toxic radical or a nitroso or hydroxylamine intermediate that
could be even more relevant for toxicity than the radical;13
(ii) GlNR1 inactivates nitazoxanide by full reduction, yielding the
corresponding amine, which is inactive;14 (iii) independently of
the reduction of xenobiotics, GlNR1 has an essential function in
an unknown metabolic pathway that is inhibited via the
binding of nitro drugs.
In order to distinguish between these hypotheses, we have
chosen a reverse genetics approach, by overexpressing GlNR1 in
G. lamblia and Eschericha coli and determined the susceptibilities
of the resulting lines to nitazoxanide and metronidazole as
compared with control, glucuronidase-transformed recombinant
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lines. Furthermore, we have analysed the expression of GlNR1 in
nitazoxanide-resistant lines of G. lamblia.
Materials and methods
Tissue culture media, biochemicals and drugs
If not otherwise stated, all biochemical reagents were from Sigma
(St Louis, MO, USA). Nitazoxanide was synthesized at the Department
of Chemistry and Biochemistry, University of Berne (C. Leumann). Nita-
zoxanide, metronidazole and albendazole were kept as 100 mM stock
solutions in DMSO at 2208C.
Axenic culture of Giardia trophozoites
Trophozoites from G. lamblia WB clone C6 were grown under anaerobic
conditions in 10 mL culture tubes (Nunc, Roskilde, Denmark) containing
modified TYI-S-33 medium.15 The nitazoxanide-resistant clone C412
was grown in the presence of 40 mM nitazoxanide. Twenty-four hours
prior to an experiment, C4 trophozoites were transferred to drug-free,
modified TYI-S-33 medium. Trophozoites were detached by incubation
on ice for 30 min. Suspended motile trophozoites were counted
(Neubauer chamber). Subcultures were initiated by adding 2–20 mL of
trophozoites in a new culture tube. Trophozoites were grown to near con-
fluence and harvested by centrifugation (600 g, 15 min, 48C). Trophozoite
pellets were washed three times with PBS, pH 7.2, and stored at 2808C.
Overexpression of recombinant GlNR1
Cloning and heterologous expression of GlNR1 and b-glucuronidase A
(GusA) in the E. coli His-tag expression vector system pET151 (pET151
directional TOPO; Invitrogen, Carlsbad, CA, USA) were carried out as pre-
viously described.11,16 Clones with high expression levels of the recom-
binant proteins11,16 were used for the re-cloning of the GlNR1 and the
GusA open reading frames into the vector pPacV-Integ (kindly provided
by A. Hehl, Institute of Parasitology, Zu¨rich, Switzerland). Applying the
XbaI and PacI sites of the vector for integration,17 a forward primer
was designed starting with the XbaI site followed by the constitutive
glutamate dehydrogenase (GDH) promoter.18 In the reverse primer, a
sequence encoding a human influenza haemagglutinin (HA) tag was
included 5′ of the PacI site (Table 1). PCRs were performed using Pfu
polymerase (Promega, Madison, WI, USA), and fragments were cloned
into the Zero Blunt TOPO vector (Invitrogen) according to the
manufacturer’s instructions. Inserts were excised with XbaI and PacI
and ligated into pPacV thus yielding pPacV-GlNR1 or pPacV-GusA. Prior
to transfection, the vectors were linearized by digestion with SwaI in
order to allow chromosomal integration of the transgene by homolo-
gous recombination. Then, transfection of G. lamblia WBC6 and selec-
tion of stable transfectants containing GusA or GlNR1 integrated into
the genome was performed as previously described via resistance to
the antibiotic puromycin.17
Antibodies and western blotting
Crude rabbit anti-GlNR1 serum was contracted from GenicBio BioTech
(Hong Kong, China). The animal had been immunized with a cocktail of
two keyhole limpet haemocyanin (KLH)-coupled peptides representing
GlNR1 coding sequence (CDS) 10–22 (RKYHPEPLPKEDL-C) and CDS 58–
70 (IAKEVSKNPRYSK-C). Antibodies were affinity-purified on recombinant
GlNR111 as described previously.19 Mouse monoclonal antibodies directed
against a-tubulin of Trypanosoma brucei and exhibiting cross-reactivity to
the analogous protein of G. lamblia clone WBC6 was kindly provided by
K. Gull (Dunn School of Pathology, University of Oxford, UK).
Total protein from E. coli and G. lamblia lines was separated by SDS–
PAGE (10% gels) under reducing conditions.20 Western blots were pre-
pared by electrophoretically transferring SDS–PAGE-separated proteins
onto nitrocellulose, and non-specific binding sites were blocked overnight
at 48C in PBS, pH 7.2 containing skimmed milk powder (2%, w/v), Tween
20 (0.1%, v/v). Primary antibodies, namely affinity-purified rabbit
anti-GlNR1 and monoclonal mouse anti-a-tubulin were diluted at 1:10
and 1:10000 in blocking solution, and blots were incubated overnight
at 48C on a horizontal shaker. Blots were then washed four times for
5 min in PBS, pH 7.2, containing 0.1% Tween 20 (PBS/Tween). The sec-
ondary antibodies, Alexa Fluor 680-conjugated goat anti-rabbit IgG and
IRDye 800-conjugated goat anti-mouse IgG (Li-Cor, Lincoln, NE, USA)
were diluted 1:5000 in Odyssey blocking solution (Li-Cor), and added to
the respective blots. Blots were then incubated for 1 h at room tempera-
ture in the dark, followed by two washes with PBS/Tween and two
washes with PBS, pH 7.2, prior to scanning in an Odyssey Infrared
Imaging System (Li-Cor). All antibodies were stored at 48C in the dark
and could be reused several times.
Determination of drug susceptibility in G. lamblia
Cultures with confluent trophozoite layers were incubated on ice for
15 min. Suspended motile trophozoites were counted and identical
Table 1. Overview of primers used in this study
Name Sequence Gene (accession number) Construct (5′ –3′)
NRexpF GATCTAGACCACAAATAACGCCTTTAATTACAGGCGCCCCAGAT
TTTAAAATATGGTTGAAGGTTATCCTG
nitroreductase Fd-NR2 (EDO80257;
replaced EAA43030.1)
GA+XbaI+GDH promoter (100%)+NR 5′
(CDS 1–19)
NRexpR GATTAATTAATCACGCGTAGTCTGGGACATGGTATGGGTATTACT
TAAATGTAATGTCGAC
GA+PacI+stop+HA-Tag+NR (CDS
730–751)
NRquantF CCTGCTGACAAGGCCGCA CDS 526–794 plus 8 of 3′ utr
NRquantR AACACCAATTACTTAAATGTAATG
ACTquantF ACATATGAGCTGCCAGATGG actin ACT (EAA39190) CDS 715–933
ACTquantR TCGGGGAGGCCTGCAAAC
HATagR CGTAGTCTGGGACATGGTAT see NRexpR HA sequence 6–25
utr, untranslated region.
Please note that the nitroreductase GlNR1 is now annotated as nitroreductase Fd-NR2. We use GlNR1 in order to be in line with our previous
publications.
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numbers of trophozoites were inoculated into 96-well plates (0.2 mL per
well) in the presence of compound or a solvent control (DMSO). The
plates were incubated under anaerobic conditions (100% N2) at 378C
for 72 h, and living trophozoites were determined by the resazurin
(Alamar blue) vitality assay as described previously.16,21 The MIC of a
compound was the concentration at which viable trophozoites could
not be detected anymore.
Determination of drug susceptibility in E. coli
Drug susceptibility of recombinant E. coli BL21(D3) lines expressing either
GlNR1 or GusA was tested by a conventional disc-diffusion agar pro-
cedure.22–24 For this purpose, bacteria were grown to stationary phase
(OD600¼1) in Luria–Bertani (LB) medium containing 100 mg/mL ampicil-
lin, and 0.3 mL of suspension was streaked on LB agar plates containing
100 mg/mL ampicillin. Whatman filter discs (5 mm diameter) were
soaked with 7 mL of nitazoxanide or metronidazole stock solution
(100 mM). Albendazole (100 mM) and kanamycin (2 mM) were included
as negative and positive controls, respectively. The discs were air-dried
for 5 min and placed on the plates. The plates were incubated under
aerobic or microaerobic (5% O2/10% CO2/85% N2) conditions at 378C
for 24 h. Then, growth inhibition zone diameters were measured and
the inhibition zone around the disc was calculated (in mm2).
RNA analysis and quantification of expression
by real-time RT–PCR
For quantification of GlNR1 expression by real-time RT–PCR, trophozoites
were grown until confluence as described above. Cells were harvested as
described above, and RNA was extracted using a Qiagen RNeasy Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
RNA was eluted with RNase-free water and stored at 2808C. First-strand
cDNA was synthesized using a Qiagen OmniscriptRT Kit (Qiagen). After
quantitative RT–PCR, expression levels were given as relative values in
arbitrary units relative to the amount of actin. The primers NRquantF
and NRquantR (Table 1) were used for the quantification of endogenous
GlNR1 expression, forming a PCR product of coding sequence 526–794
plus 8 nt of the untranslated region.12 The primers NRquantF and
HATagR (Table 1) were used for the quantification of exogenous GlNR1
expression. The primers ACTquantF and ACTquantR (Table 1) were used
for the quantification of a constitutively expressed gene, namely the
G. lamblia actin transcript.12
Quantitative RT–PCR was carried out on a LightCyclerTM Instrument
(Roche Diagnostics, Rotkreuz, Switzerland) using SYBR Green (Qiagen)
as a double-stranded DNA-specific fluorescent dye and continuous fluor-
escence monitoring as described previously.25 All PCRs were performed in
triplicate. PCR was started by initiating the ‘Hot-Start’ Taq DNA polymer-
ase reaction at 958C (15 min). Subsequent DNA amplification was carried
out in 40 cycles including denaturation (948C, 15 s), annealing (608C,
30 s) and extension (728C, 30 s); temperature transition rates in all
cycle steps were 208C/s. Fluorescence was measured at 828C during
the temperature shift after each annealing phase in the ‘single’ mode.
Fluorescence signals from the amplification products were quantitatively
assessed by applying the standard software (version 3.5.3) of the Light-
Cycler Instrument. Quantification of PCR products was performed during
the log phase of the reaction and was achieved by using the secondary
derivative maximum mode for plotting of the fluorescence signals
versus the cycle numbers. Respective mean values from triplicate deter-
minations were taken for the calculation. From the quantitative RT–PCR,
mean values (+SEM) from triplicate determinations were assessed and
expression levels of the GlNR1 gene were given as values in arbitrary
units relative to the amount of constitutively expressed ‘housekeeping’
gene actin.
Statistical methods
For statistical analysis of the results from the drug treatment assays with
G. lamblia and E. coli and from the determination of GlNR1 expression
levels, the Student’s t-test in the GraphPad Prism 5 program (GraphPad
Software, San Diego, CA, USA) was applied. Differences exhibiting
P values of ,0.05 or ,0.001 were considered significant or highly signifi-
cant, respectively. IC50 values were calculated as described previously.
16
Results
Expression of recombinant GlNR1 in G. lamblia
strain WBC6
In order to elucidate the importance of nitroreductase for sus-
ceptibility to nitro drugs, G. lamblia WBC6 was transfected with
either GlNR1 or GusA as a control, both under control of a consti-
tutive promoter. After selection of stable transformants, the
mRNA levels of recombinant GlNR1 were determined by quanti-
tative RT–PCRs specific for endogenous and recombinant
GlNR1. The corresponding protein expression levels were
assessed by western blotting. Endogenous GlNR1 mRNA levels
were unchanged in WBC6-GlNR1 as compared with WBC6-
GusA. mRNA levels of recombinant GlNR1 and endogenous
GlNR1 were three times higher than those of endogenous
GlNR1 alone. As shown by immunoblot, enhanced expression
of GlNR1 was also clearly visible at the protein level (Figure 1a
and b).
WBC6-GlNR1 is more susceptible to nitro drugs
than WBC6-GusA
WBC6-GlNR1 and WBC6-GusA were grown in the presence of
either of the two nitro drugs nitazoxanide and metronidazole,
and albendazole as a control. WBC6-GlNR1 was more susceptible
to the two nitro drugs than WBC6-GusA with regard to the corre-
sponding IC50 values (Table 2) and particularly at concentrations
between 1.56 and 6.25 mM metronidazole and 3.13 mM nitazox-
anide. These values have asterisks in the figure. In contrast,
albendazole inhibited growth of both lines identically (Figure 2).
E. coli expressing recombinant GlNR1 exhibit increased
susceptibility to nitazoxanide under semi-aerobic
growth conditions
The previous results suggested that GlNR1 activated rather than
inactivated nitro drugs, and thus increased their efficacy. It
could, however, not be ruled out that this effect was due to
unknown functions of nitroreductases in metabolic pathways
specific to Giardia.
To test whether the effect observed above in Giardia could be
repeated in a completely different cellular environment, we
generated recombinant E. coli lines producing either GlNR1 or
heterologous control enzyme GusA. In order to verify the
expression of the recombinant proteins, immunoblot analyses
of E. coli transformed with GlNR1 and GusA were performed.
E. coli transformed with GlNR1 produced the recombinant
protein even under non-induced conditions. Cross-reaction of
the anti-GlNR1 antibody with endogenous E. coli proteins was
not observed (Figure 3a). Since overproduction of both GlNR1
and control protein GusA in IPTG-induced E. coli strongly
Nitroreductase and nitro drugs in G. lamblia
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reduced growth, non-induced, recombinant E. coli cultures were
chosen for growth inhibition assays under aerobic and semi-
aerobic growth conditions.
Under aerobic as well as semi-aerobic growth conditions, nita-
zoxanide did not affect growth of control bacteria. Under semi-
aerobic conditions, bacteria expressing GlNR1 were significantly
more susceptible to nitazoxanide than control bacteria.
However, under aerobic conditions, nitazoxanide had no inhibi-
tory effect (Figure 3b). Interestingly, metronidazole inhibited
growth of control or of GlNR1-transformed bacteria even under
aerobic conditions. Bacteria expressing GlNR1 exhibited a slightly
more pronounced inhibition under semi-aerobic conditions
(Figure 3b). Kanamycin inhibited both transformed lines similarly
with inhibition zones of 150 mm2 in both cases. Albendazole
did not affect growth in either line. No significant differences in
Table 2. IC50 values of the drug susceptibility assays presented in
Figure 2
Drug G. lamblia GusA, mM (SEM) G. lamblia GlNR1, mM (SEM)
Metronidazole 4.5 (0.9) 2.3 (0.5)
Nitazoxanide 1.5 (0.3) 1.1 (0.2)
Albendazole 0.04 (0.01) 0.04 (0.01)
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Figure 1. Overexpression of G. lamblia nitroreductase (GlNR1) in
transgenic G. lamblia WBC6. (a) Quantification of GlNR1 mRNA levels by
RT–PCR. Trophozoites were grown to confluence. RNA was extracted
and reverse transcribed into cDNA. Endogenous (GlNR1 endo) and
chimeric GlNR1 plasmid-encoded, exogenous (GlNR1 exo) transcripts of
GlNR1 were quantified in relation to actin. Means+SEM are given for
triplicates. Three asterisks indicate that values were different at a
highly significant level, P,0.01, as determined by Student’s t-test. (b)
Western blot showing GlNR1 in control (GusA) and
GlNR1-overexpressing (GlNR1) trophozoites. Trophozoites were grown to
confluence, harvested and processed for SDS–PAGE. Positions of bands
corresponding to endogenous a-tubulin reference protein and GlNR1
are indicated. This figure appears in colour in the online version of JAC
and in black and white in the print version of JAC.
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Figure 2. Drug susceptibility of G. lamblia WBC6 expressing E. coli GusA
and G. lamblia nitroreductase (GlNR1). 96-well plates were inoculated
with 2×102 GusA or GlNR1 trophozoites per well and grown in the
presence of nitazoxanide (a), metronidazole (b) or albendazole (c) at
various concentrations. After 72 h, growth of cells was monitored by a
vitality assay based on the reduction of resazurin (Alamar blue) to a
pink product that was assayed fluorimetrically. Mean values of the
relative fluorescence units normalized to the control values (+SEM) are
given for four replicates. Asterisks indicate significant differences
between GusA and GlNR1 trophozoites (paired t-test, two-sided,
P,0.05).
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susceptibility to nitro drugs between the two recombinant E. coli
lines were detected when they were grown aerobically.
Nitazoxanide-resistant Giardia have lower GlNR1
expression levels
As shown above, overexpression of GlNR1 is correlated with a
higher susceptibility to nitro drugs. Unfortunately, we could not
show the opposite, i.e. a lower susceptibility in nitroreductase-
silenced cells since expression of antisense constructs under
the same conditions as described above were lethal in our
hands, and trophozoites expressing a GlNR1-antisense construct
under a weaker promoter were so severely impaired in growth
that drug susceptibility assays could not be performed (data
not shown). Therefore, we induced resistance to nitazoxanide
in WBC6 as described earlier for the previously characterized
line derived from clone C412 and obtained a nitazoxanide-
resistant line (NTZII) independently of clone C4. MIC values for
both lines were .100 mM as compared with 25 mM for the wild-
type. The relative mRNA levels of GlNR1 in clone C4 were .4.9
times lower than in WBC6, and also significantly lower than in
line NTZII (Figure 4a). The lower expression of GlNR1 in
nitazoxanide-resistant lines was also shown to occur at the
protein level (Figure 4b).
Discussion
Metronidazole and other antiparasitic nitro drugs are con-
sidered to be prodrugs, which are activated by partial reduction
forming a toxic radical26 or a partially reduced nitroso or hydro-
xylamine intermediate.13 On the other hand, complete
reduction detoxifies nitro compounds, and thus allows some
bacteria to use highly toxic compounds such as trinitrotoluene
as carbon sources.27 Overexpression of target enzymes yielding
toxic radicals would then correlate with higher susceptibility,
while overexpression of target enzymes performing total
reduction would result in increased resistance. Our results
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Figure 3. Susceptibility of E. coli BL21, expressing GusA or GlNR1 to
nitazoxanide (NTZ) and metronidazole (MTZ). (a) Coomassie-stained gel
(loading control) and corresponding western blot showing the
expression of GlNR1 in GlNR1-transformed E. coli. (b) Drug susceptibility
assays. Lines were plated, discs containing the drugs were added as
described and plates were incubated under aerobic or semi-aerobic
(5% O2/10% CO2/85% N2) conditions. After 24 h, diameters of
inhibition zones were determined and surface areas of inhibition zones
were calculated. Means+SEM are given for three replicates. Three
asterisks indicate that values were different at a highly significant level
(paired t-test, one-sided, P,0.001). This figure appears in colour in the
online version of JAC and in black and white in the print version of JAC.
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Figure 4. Differential expression of G. lamblia nitroreductase (GlNR1) in
G. lamblia WBC6 and drug-resistant derivatives of WBC6. (a)
Quantification of GlNR1 mRNA levels by RT–PCR. Trophozoites were
grown to confluence. RNA was extracted and reverse transcribed into
cDNA. Transcripts of GlNR1 were quantified in relation to actin.
Means+SEM are given for triplicates. Three asterisks indicate that
values were different at a highly significant level, P,0.001, as
determined by Student’s t-test. (b) Western blot showing GlNR1 in
wild-type WBC6 (wt), WBC6 grown on successively increasing
nitazoxanide concentrations (strain NTZII) and the previously described
nitazoxanide/metronidazole-resistant clone C4 (C4). Trophozoites were
grown to confluence, harvested and processed for SDS–PAGE. Positions
of bands corresponding to endogenous a-tubulin reference protein and
GlNR1 are indicated. This figure appears in colour in the online version
of JAC and in black and white in the print version of JAC.
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presented above suggest that in Giardia, the nitroreductase
GlNR1 is one of the enzymes with the ability to perform
partial reduction of nitro compounds: overexpression of GlNR1
in G. lamblia is followed by higher susceptibility to both metro-
nidazole and nitazoxanide. Interestingly, GlNR1 has a ferredoxin
domain, which nicely corroborates the findings about the invol-
vement of ferredoxin as an electron donor for the reduction of
metronidazole and other nitro compounds in Giardia. Recent
findings have shown that PFOR is not the only possible electron
donor for this reduction.28 Our findings suggest that GlNR1 is
another donor, thus explaining resistance formation without
involvement of the PFOR system.
However, since trophozoites transformed with antisense con-
structs are not viable, it cannot be ruled out that GlNR1 carries
out some still unknown, but essential, functional activities in
the intermediate metabolism of Giardia. Therefore, the results
obtained with E. coli are of particular interest since they indicate
that GlNR1 works in a different cellular environment in the same
way as in Giardia (at least with respect to nitro drugs). Moreover,
since E. coli grow well under aerobic as well as under semi-
aerobic conditions, it is possible to explore the effects of these
conditions on GlNR1. E. coli that express GlNR1 are susceptible
to nitazoxanide under semi-aerobic conditions, but not under
aerobic conditions. This corroborates our previous findings that
recombinant GlNR1 does not reduce nitazoxanide in vitro under
aerobic conditions.11 The situation is quite different in the pres-
ence of metronidazole. Under both aerobic and semi-aerobic
conditions, the two E. coli lines are clearly susceptible to metro-
nidazole, with only slight enhancement in E. coli expressing
GlNR1. This indicates that in E. coli reduction of metronidazole,
but not of nitazoxanide, may be due to endogenous E. coli
nitroreductases expressed even under aerobic growth conditions,
thus by metabolic pathways different from PFOR or GlNR1-
homologous nitroreductases, since both systems are absent
from the E. coli genome. In this context it is noteworthy to
mention that most of the literature on the antibacterial effects
of metronidazole and related nitro drugs concern anaerobic or
semi-aerobic bacteria such as Helicobacter pylori. Since E. coli
obviously is susceptible to metronidazole, it represents an ideal
model of choice to study this drug. This susceptibility has been
reported earlier by other authors.24 Several nitroreductases
have been identified in the E. coli genome. Of these, the Ntr
gene is most interesting, since transfection of mammalian
tumour cells and expression of Ntr rendered these cells metroni-
dazole sensitive.29,30 Another interesting candidate is NfsA, a
nitroreductase with a good affinity to nitrofurazones and other
nitroaromatic compounds.31
These results, and the fact that nitazoxanide and metronida-
zole resistance in G. lamblia correlated with strongly reduced
GlNR1 expression, suggested participation of the nitroreductase
GlNR1 in activation of nitro drugs. Thus, the expression level of
this enzyme clearly represents a key factor for the determination
of susceptibility versus resistance to nitro drugs in G. lamblia.
However, previous studies on differential gene expression pat-
terns in wild-type and resistant lines have shown that the
expression levels of a variety of genes are affected. This indicated
that resistance formation takes place on a multigenic rather than
a monogenic level.32 Further studies will be necessary to provide
coherent information on the complex pathways that determine
the antigiardial activity of nitro compounds.
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